Zobrazeno 1 - 10
of 647
pro vyhledávání: '"ABT‐199"'
Autor:
Ying Cui, Xiaoya Shao, Haiping Yang, Jingyi Xin, Yuanyuan Liu, Mingxiao Zhang, Chuanyue Sun, Ge Chen, Guomin Shen, Xueqiong Meng, Yixiang Chen
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Although clinical outcomes in chronic lymphocytic leukemia (CLL) have greatly improved with several approved small molecular inhibitors, acquired resistance does occur, leading to disease progression and eventual death. Thus, the effort to explore no
Externí odkaz:
https://doaj.org/article/d8a23119e1db438fbc1f16b9e7bf1eaa
Publikováno v:
Molecular Oncology, Vol 16, Iss 20, Pp 3735-3753 (2022)
To investigate the effect of Apatinib (an inhibitor targeting VEGFR‐2) enhances chemosensitivity of ABT‐199 on diffuse large B‐cell lymphoma (DLBCL). Viability assay and flow cytometric assay for determining apoptosis, cell cycle, mitochondrial
Externí odkaz:
https://doaj.org/article/0f0419a02bfb4251988f27803a5a352e
Publikováno v:
Cell Journal, Vol 24, Iss 8, Pp 473-480 (2022)
Objective: Chronic lymphoid leukemia (CLL) is the most common type of leukemia among adults. Increased levels of Mcl-1 and Bcl-xL is linked to resistance to Bcl-2 inhibitors including ABT-199. In this study, we investigated the effect of miRNA-16-1 o
Externí odkaz:
https://doaj.org/article/8e549cae0f9b4a188335c924c02f6ee8
Autor:
Thomas F. Eleveld, Lindy Vernooij, Linda Schild, Bianca Koopmans, Lindy K. Alles, Marli E. Ebus, Rana Dandis, Harm van Tinteren, Huib N. Caron, Jan Koster, Max M. van Noesel, Godelieve A. M. Tytgat, Selma Eising, Rogier Versteeg, M. Emmy M. Dolman, Jan J. Molenaar
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionMutations affecting the RAS-MAPK pathway occur frequently in relapsed neuroblastoma tumors and are associated with response to MEK inhibition in vitro. However, these inhibitors alone do not lead to tumor regression in vivo, indicating th
Externí odkaz:
https://doaj.org/article/f113f91a5d74419a8ac27a8cd36776b9
Autor:
Li Chen, Xudong Jiang, Si Gao, Xueping Liu, Ying Gao, Audrey Siew Foong Kow, Chau Ling Tham, Ming Tatt Lee
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
ABT-199 (venetoclax) is the first-in-class selective B-cell lymphoma 2 (BCL2) inhibitor, which is known to be ineffective towards liver cancer cells. Here, we investigated the efficacy and the underlying molecular processes of the sensitization effec
Externí odkaz:
https://doaj.org/article/9dbc20f0844b466fbda06614ba842717
Autor:
Moaath K. Mustafa Ali, Elizabeth M. Corley, Hanan Alharthy, Kathryn A. F. Kline, Jennie Y. Law, Seung Tae Lee, Sandrine Niyongere, Vu H. Duong, Ashkan Emadi, Maria R. Baer
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
There is a deficiency of real-world data on the impact of combining venetoclax (VEN) with hypomethylating agents (HMAs) in newly diagnosed acute myeloid leukemia (AML) patients. We conducted a single-center, propensity-adjusted retrospective cohort s
Externí odkaz:
https://doaj.org/article/a8829a8dd74a40fc9b48d7be3211c6d6
Autor:
Katarzyna Bobeff, Agata Pastorczak, Zuzanna Urbanska, Walentyna Balwierz, Edyta Juraszewska, Jacek Wachowiak, Katarzyna Derwich, Magdalena Samborska, Krzysztof Kalwak, Iwona Dachowska-Kalwak, Paweł Laguna, Iwona Malinowska, Katarzyna Smalisz, Jolanta Gozdzik, Aleksandra Oszer, Bartosz Urbanski, Maciej Zdunek, Tomasz Szczepanski, Wojciech Mlynarski, Szymon Janczar
Publikováno v:
Children, Vol 10, Iss 4, p 745 (2023)
Venetoclax, the best established BH3-mimetic, is a practice-changing proapoptotic drug in blood cancers in adults. In paediatrics the data are fewer but exciting results were recently presented in relapsed or refractory leukaemias demonstrating signi
Externí odkaz:
https://doaj.org/article/98a8dfe4a61d4af7bc0b568d64fad2c4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Stefania Fiorcari, Rossana Maffei, Claudio Giacinto Atene, Nicolò Mesini, Monica Maccaferri, Giovanna Leonardi, Silvia Martinelli, Ambra Paolini, Vincenzo Nasillo, Giulia Debbia, Leonardo Potenza, Mario Luppi, Roberto Marasca
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
Chronic lymphocytic leukemia (CLL) has experienced a clinical revolution—thanks to the discovery of crucial pathogenic mechanisms. CLL is still an incurable disease due to intrinsic or acquired resistance of the leukemic clone. Venetoclax is a Bcl-
Externí odkaz:
https://doaj.org/article/30be9babf7f64fe391dce5b720f44a01
Autor:
Amanda B. Kagan, Blake S. Moses, Bryan T. Mott, Ganesha Rai, Nicole M. Anders, Michelle A. Rudek, Curt I. Civin
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
Acute myeloid leukemia (AML) remains a devastating disease, with low cure rates despite intensive standard chemotherapy regimens. In the past decade, targeted antileukemic drugs have emerged from research efforts. Nevertheless, targeted therapies are
Externí odkaz:
https://doaj.org/article/2cf6566fed2a4ca3b0fec12ce23940fd